Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis

NCT06810050 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis (AD)

Interventions

DRUG: CGB-500 with 0.5% tofacitinib
DRUG: CGB-500 Ointment with 1% tofacitinib
DRUG: Vehicle (placebo)

Sponsor

CAGE Bio Inc.